Navigation Links
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Date:8/6/2012

Therapeutics Market, Germany, Revenue ($m), 2006- 2011 29

Table 12: Retinal Vein Occlusion Therapeutics Market, Germany, Forecasts ($m), 2011- 2019 30

Table 13: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2006- 2011 31

Table 14: Retinal Vein Occlusion Therapeutics Market, Italy, Forecasts ($m), 2011- 2019 32

Table 15: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2006- 2011 33

Table 16: Retinal Vein Occlusion Therapeutics Market, Spain, Forecasts ($m), 2011- 2019 34

Table 17: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2006- 2011 35

Table 18: Retinal Vein Occlusion Therapeutics Market, The UK, Forecasts ($m), 2011- 2019 36

Table 19: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2006- 2011 37

Table 20: Retinal Vein Occlusion Therapeutics Market, Japan, Forecasts ($m), 2011- 2019 38

Table 21: Lucentis Phase III Clinical Trial Details 43

Table 22: Number (%) of Patients With ? 15 Letter Improvement from Baseline in Best-Corrected Visual Acuity 44

Table 23: Adverse Reactions Reported by >2% of Patients in the First Six Months 44

Table 24: Retinal Vein Occlusion Therapeutics, Phase III Pipeline, 2012 47

Table 25: Retinal Vein Occlusion Therapeutics, Phase II/III Pipeline, 2012 47

Table 26: Retinal Vein Occlusion Therapeutics, Phase II Pipeline, 2012 48

Table 27: Retinal Vein Occlusion Therapeutics, Phase I/II Pipeline, 2012 48

Table 28: RVO Therapeutics - Most Promising Drugs Under Clinical Development, 2012 51

Table 29: Eylea Phase III Clinical Trial Details 53

Table 30: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2012 54

Table 31: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase, 2012 55

Table 32: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status, 2012 56

Table 33: Retinal Vein Occlusion
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... treating MCLs nonsurgically, study findsROSEMONT, Ill., March 2 ... (MCL) may be treated successfully without surgery, according to ... of The Journal of the American Academy of ... review,s authors found, is properly diagnosing and understanding the ...
... Md., March 2 TissueGene, Inc. announced today that ... (KLS) has received regulatory allowance from the Korea Food ... clinical trial of TissueGene-C (TG-C) in patients with severe ... for the localized delivery of allogeneic human cells expressing ...
Cached Medicine Technology:Treating Knee Ligament Injuries 2Treating Knee Ligament Injuries 3TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee 2
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
(Date:4/23/2014)... whose testosterone falls below normal levels are more likely ... have heart disease and type 2 diabetes. A new ... further testing and possible treatment is described in an ... peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The ... Men,s Health website at http://www.liebertpub.com/jmh . ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... cabinet, may help in easing out prostate problem, according to ... known to help in the prevention of arthritic inflammations, heart ... The researchers say that now it may help solve some ... enlarged prostates. ,It may help reduce the urinary ...
... view of The Sterling Council, of levying ?1 a week for ... refuses to buy. The complainant, Mrs. C, has not minced words ... the society, and truly a mockery of the free care provided ... emergency care system in her home in 2002. This allowed emergency ...
... of the University of Sao Paulo Medical School in Brazil ... getting the best care in case of chronic coronary artery ... to be published in the September edition of the Journal ... to receive their physician-recommended treatment showed a significantly lower incidence ...
... A British tourist in Hong Kong is suspected of having the ... been named and was admitted to a Hog Kong hospital// after ... man came to the country on April 4 and was admitted ... Chinese origin and underwent intestinal surgery earlier. Hong Kong health department ...
... A $500,000 television and radio ad campaign blaming GOP ... prescription drug program has been launched by the// Association ... ,The ad campaign accusing the lawmakers for blocking provisions ... companies for the best prescription cost has been targeted ...
... techniques and concussions among high school athletes found that ... of// concussion. ,In the current ... Medicine in Philadelphia and co-author Dr. Tracey Covassin of ... directors of athletics from Pennsylvania and New Jersey high ...
Cached Medicine News:Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 3Health News:Ad Campaign Targeting Republicans On Medicare Prescription Drug Program 2Health News:Proper Fitting Of Football Helmets Essential To Prevent Concussion 2
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures....
The Shandon Linistain GLX Linear Stainer is an economical mid-size linear stainer featuring 28 staining stations and a heater/dryer with fume control by a charcoal filter....
... Finesse E+ is a precision ... specimen advance with manual cutting. ... is easy to operate. Coarse ... the option of manually advancing ...
Medicine Products: